AUTEN-67 is an autophagy-enhancing drug candidate that increases autophagic flux in cell lines and in vivo models. It hampers the progression of neurodegenerative symptoms in a Drosophila model of Huntington's disease. It is developed by Velgene Biotechnology Ltd.
References